Navigation Links
Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
Date:6/3/2008

CORONA, Calif., June 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that it has received final approval from the U.S. Food and Drug Administration ("FDA") of its Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Capsules USP in the 10mg, 20mg and 40mg strengths.

Watson has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for the 40mg strength. Watson's marketing exclusivity will begin upon commercial launch. The Company plans to launch its Omeprazole Delayed-Release product during the third quarter of 2008. The specific launch date will depend upon the timing of product validation activities and manufacturing of launch quantities. Watson plans to launch only the 40 mg strength.

Omeprazole is the generic equivalent to AstraZeneca's Prilosec(R) Delayed-Release Capsules USP and is indicated for the short-term treatment of active duodenal ulcer. For the 12-months ending March 2008, Prilosec(R) Delayed-Release Capsules and its generic equivalents had total U.S. sales of approximately $240 million, according to IMS Health.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is a leading specialty pharmaceutical company that develops, manufactures, markets, sells and distributes brand and generic pharmaceutical products. Watson pursues a growth strategy combining internal product development, strategic alliances and collaborations and synergistic acquisitions of products and businesses.

For press releases and other company information, visit Watson Pharmaceuticals' Web site at

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
2. Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
3. Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference
4. Watson to Present at the Bank of America 2008 Healthcare Conference
5. Texas Senator Kirk Watson Honored as Champion for Children by the AMERIGROUP Foundation
6. Watson Files Application for Generic SEASONIQUE(R)
7. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
8. Few Employers Addressing Workplace Stress, Watson Wyatt Surveys Find
9. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
10. Medical Cost Increases to Accelerate Worldwide Over Next Five Years, Watson Wyatt Poll Finds
11. Watson to Distribute Alendronate Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., , PEMBROKE, Bermuda, Dec. 4 /PRNew... Holdings, Ltd (NYSE: AWH ) today announced that...ficer, and Jack Sennott, Executive Vice,President ...enting at the 2009,Goldman Sachs U.S. Financial Se...Conference Center in New York City on Tuesday, Dec...
(Date:12/4/2009)..., , ANAHEIM, Calif., Dec. 4 /PRNewswire/...scent Healthcare, was selected as a finalist for t...forming Crescent,s business with the power of clou...ased on their innovative usage of Salesforce CRM o... customer success to their sales, marketing, partn...
(Date:12/4/2009)..., Working with mice, scientists at Johns Hopkins...ave shown that a protein made by a gene called "Tw...ately distinguish stem cells that drive aggressive...r cells. , Building on recent work suggesting th...in breast tumors that drives breast cancer, scient...
(Date:12/4/2009)...Outcomes same whether procedure done immediately o... Dec. 4 (HealthDay News) -- Timing of surgical rep...juries may not affect patient outcome, a new study...esult from traumatic knee dislocations that can oc...s. The optimal time to perform surgery to repair t...
(Date:12/4/2009)...Research and surveillance urged for at-risk patien...ews) -- Some childhood cancers, particularly Ewing... the risk of late recurrence, U.S. researchers hav... 12,795 five-year survivors of the most common ped...Cancer Survivor Study. , The researchers found ...
Breaking Medicine News(10 mins):Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Potential new 'twist' in breast cancer detection 2Health News:Potential new 'twist' in breast cancer detection 3Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2
... screenwriters have a lower life expectancy than n...ainly improve your health and longevity - but it d..., Texas, reveal the health risks of winning an Aca...4 years than mere nominees. This is despite having...
...rong connection between celiac disease and diabete...eliac disease in people with type 1 diabetes is ab.... Doctors have uncovered a new finding for diabeti...tion to gluten. Both CD and diabetes are common ch...
...ciation for Continence, a new study shows early in...evalence of incontinence. Incontinence is loss of ...any conditions can cause incontinence,// including... ...
...t they may one day be able to reverse some cases o...indings from an animal study that show infertile m...on to produce offspring.// According to resea...f those are a result of problems with sperm produc...
...th Care System, obese adults who undergo 'stomach ...covered 'hunger hormone' than either normal-weight... Dr. David E. Cumming from the Puget Sound Health...oblems such as type 2 diabetes and other chronic d...
... play a role in reducing the number of childhood d...who tested three different methods of zinc adminis...zinc reduced the risk of prolonged diarrhea// defi...er or the child's caregiver. More than 3 mill...
Other Medicine News:Health News:Decrease of 'Hunger Hormone' after Obesity Surgery 2
(Date:12/4/2009)...., Dec. 4 AstraZeneca (N...Drug Administration (FDA) has approved once-daily ...elease Tablets as adjunctive (add-on) treatment to...isorder (MDD). SEROQUEL XR is the only medication ...or depressive disorder as adjunctive therapy and a...
(Date:12/3/2009)...Dec. 3 A genetic variati...g a potentially life-threatening blood disorder if...emicals is one of several medical discoveries scie...ics (NYSE: DGX ) will present during the 51st Am...and Exposition, December 5-8, 2009, in New Orleans...
(Date:12/3/2009)...el., Dec. 3 ParagonRx, a Delaware-...management and optimal medication use, will host a...raft guidance on REMS - Risk Evaluation Mitigation... lifecycle management. Dr. Gary Slatko, chief med...d risk management programs, will lead the one-hour...
Breaking Medicine Technology:US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3No Increase in Brain Tumors Seen From Cell Phones 62563 1No Increase in Brain Tumors Seen From Cell Phones 62563 2No Increase in Brain Tumors Seen From Cell Phones 62563 3RN SuperUnion Founding Convention Opens Monday 62559 1RN SuperUnion Founding Convention Opens Monday 62559 2Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 1Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 2Wayne State Researchers Report a Possible Proofreading Step in DNA Synthesis by Observing Single Molecules of DNA Polymerase 62555 3
...the human vaccine business unit of Schering-Plough...it has reached an important milestone with the ini... program for SCH 900795, a new intranasal Live Att...al use. , , The candidate vaccine is composed of ... by the World Health Organization (WHO) for season...
...esented at USCAP Meeting , , SOUTH SAN FRANCISCO,...sdaq: RIGL ) today announced the enrollment of t...al trial of R788 (fostamatinib disodium) in patien...ymphoma (PTCL). The clinical trial,s primary obje... bio-available Syk kinase inhibitor, in patients s...
Other Medicine Technology:Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 2Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development 3Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 2Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas 3
...YDON is a long-pulsed Nd:YAG laser system with a w...deep-lying, superficial as well as red and blue ve...pilation in patients with darker skin types (1 to ...vement of skin texture. The handpieces special des...
...he UroVysion Bladder Cancer Kit (UroVysion Kit) is...7, 17, and loss of the 9p21 locus via fluorescence...rom persons with hematuria suspected of having bla...tended for use, in conjunction with and not in lie...
The BTA TRAK® Assay
ARION Long-Pulsed Alexandrite Laser System
Medicine Products: